cardiopulmonary bypass in patients?

Abstract

These results indicate that aprotinin at doses currently used to reduce blood loss has no significant influence on the systemic inflammatory response during moderate hypothermic cardiopulmonary bypass in human subjects, as assessed by the mediators measured in this study.

Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion

“…Study drugs were delivered in identical volumes. Staff in the operating room and in the intensive care unit were not aware of the treatmentParticipants65 patients undergoing primary coronary artery bypass graft surgery were randomised to one of two groups:Tranexamic acid group: n = 29, M/F = 18/11, mean (sd) age = 62 (9.2) yearsControl group (placebo) (n = 31), M/F = 25/6, mean (sd) age = 59 (8.7) years NB: Five patients were excluded from the final analysis.Interventions Tranexamic acid group received a loading dose of 10mg/kg of TXA before skin incision, followed by a continuous infusion of 1mg/kg/hr for 5 hours.Control group received a bolus of normal saline solution in an identical syringe and a continuous infusion of normal saline for 5 hours. Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, allogeneic blood usage (units), fresh frozen plasma usage (units), blood loss, mortality, re-operation for bleedingNotesQuality assessment score (Schulz criteria): 4/7Transfusion protocol used Risk of bias Item Authors’ judgement Description Adequate sequence generation?UnclearUnclearAllocation concealment?NoInadequate - sealed envelopesBlinding?All outcomesYesDouble blind Schmartz 2003…”